This roundtable series reviews the use of B-cell maturation antigen–targeted treatments in patients with relapsed/refractory multiple myeloma, as discussed by participants at virtual live events.
Part 1: Selecting Treatment Options for Relapsed/Refractory Multiple Myeloma
January 26th 2022During a live virtual event, Natalie Callander, MD, discussed possible treatment options for a patient who relapsed several years after successful treatment of multiple myeloma with bortezomib, lenalidomide, and dexamethasone.